Armata Pharmaceuticals, Inc. 8-K

What Happened

• Armata Pharmaceuticals (ARMP) announced that the Board appointed Dr. Daniel Gilmer, age 39, as a director effective April 24, 2026. He will serve until the company’s next annual shareholders’ meeting. Committee assignments have not yet been determined.

Key Details

• Dr. Gilmer will receive the company’s standard non‑management director cash retainer of $40,000 per year.
• He is expected to receive a stock option to purchase 51,280 shares, vesting in equal installments over three years; exercise price = fair market value on grant date.
• He will be eligible for additional equity awards under the company’s 2016 Stock Incentive Plan and is party to the company’s standard indemnity agreement.
• Company disclosed no related-party arrangements, family relationships with executives/directors, or reportable transactions involving Dr. Gilmer.

Why It Matters

• This is a board-level personnel change that may affect governance and oversight at Armata. The option award creates potential future share dilution if exercised; the cash retainer is a modest recurring board expense. The filing confirms there are no related-party concerns disclosed, and committee roles and any further compensation details will be set by the Board.